Enanta Pharma Highlights New Data From Co.'s Phase 2a Human Challenge Study Of EDP-938 For RSV Showed Highly Statistically Significant Reductions in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay